Growth Metrics

Rigel Pharmaceuticals (RIGL) Other Non-Current Assets (2010 - 2026)

Rigel Pharmaceuticals' quarterly Other Non-Current Assets came in at $2.4 million in Q1 2026, up 55.47% year-on-year from $1.5 million in Q1 2025, and up 23.53% quarter-over-quarter from $1.9 million in Q4 2025.

Rigel Pharmaceuticals has reported Other Non-Current Assets for 17 years, with the latest figure at $2.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Other Non-Current Assets rose 55.47% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (up 55.47% YoY), and the FY2025 full-year result was $1.9 million, up 24.95% from the prior year.
  • Other Non-Current Assets for Q1 2026 stood at $2.4 million, up from $1.9 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $5.0 million in Q3 2023, with the low at $403000.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $2.2 million, with a median of $1.5 million recorded in 2024.
  • Year-over-year, Other Non-Current Assets soared 923.97% in 2023 and sank 75.49% in 2025.
  • Tracing RIGL's Other Non-Current Assets over 5 years: stood at $640000.0 in 2022, then soared by 377.34% to $3.1 million in 2023, then slumped by 50.02% to $1.5 million in 2024, then gained by 24.95% to $1.9 million in 2025, then increased by 23.53% to $2.4 million in 2026.
  • The last three Other Non-Current Assets figures came in at $2.4 million (Q1 2026), $1.9 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 12.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 60,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.26 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 2.13 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 63.55 Mn
10 Rigel Pharmaceuticals 551.62 Mn 404.94 Mn 54.21 Mn 2.36 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 2.36 Mn
Dec 31, 2025 1.91 Mn
Sep 30, 2025 1.17 Mn
Jun 30, 2025 4.18 Mn
Mar 31, 2025 1.52 Mn
Dec 31, 2024 1.53 Mn
Sep 30, 2024 4.76 Mn
Jun 30, 2024 4.74 Mn
Mar 31, 2024 4.32 Mn
Dec 31, 2023 3.06 Mn
Sep 30, 2023 4.96 Mn
Jun 30, 2023 541,000.00
Mar 31, 2023 542,000.00
Dec 31, 2022 640,000.00
Sep 30, 2022 484,000.00
Jun 30, 2022 403,000.00
Mar 31, 2022 464,000.00
Dec 31, 2021 974,000.00
Sep 30, 2021 935,000.00
Jun 30, 2021 840,000.00
Mar 31, 2021 818,000.00
Dec 31, 2020 824,000.00
Sep 30, 2020 820,000.00
Jun 30, 2020 653,000.00
Mar 31, 2020 661,000.00
Dec 31, 2019 696,000.00
Sep 30, 2019 695,000.00
Jun 30, 2019 713,000.00
Mar 31, 2019 729,000.00
Dec 31, 2018 735,000.00
Sep 30, 2018 652,000.00
Jun 30, 2018 678,000.00
Mar 31, 2018 754,000.00
Dec 31, 2017 803,000.00
Sep 30, 2017 770,000.00
Jun 30, 2017 704,000.00
Mar 31, 2017 730,000.00
Dec 31, 2016 764,000.00
Sep 30, 2016 800,000.00
Jun 30, 2016 842,000.00
Mar 31, 2016 1.06 Mn
Dec 31, 2015 1.11 Mn
Sep 30, 2015 1.17 Mn
Jun 30, 2015 1.02 Mn
Mar 31, 2015 1.06 Mn
Dec 31, 2014 1.09 Mn
Sep 30, 2014 1.41 Mn
Jun 30, 2014 1.46 Mn
Mar 31, 2014 1.48 Mn
Dec 31, 2013 1.53 Mn
Sep 30, 2013 1.59 Mn
Jun 30, 2013 1.64 Mn
Mar 31, 2013 1.70 Mn
Dec 31, 2012 1.76 Mn
Sep 30, 2012 1.83 Mn
Jun 30, 2012 1.88 Mn
Mar 31, 2012 1.93 Mn
Dec 31, 2011 1.99 Mn
Sep 30, 2011 2.05 Mn
Jun 30, 2011 2.13 Mn
Dec 31, 2010 2.24 Mn